This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor（ER）, proges...This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor（ER）, progesterone receptor（PR） and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry.Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2%（79/521）, 26.9%（140/520） and 44.8%（225/502）, respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5%（39/521）, 13.3%（69/520） and 21.1%（106/502） of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7%（40/521）, 13.6%（71/520）and 23.7%（119/502） of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.展开更多
Objective: The purpose of this study was to explore the optimal cutoffs of the three parameters of Ki67 during NAC for predicting patient prognosis and investigate whether the optimal cutoffs of the Ki67 values were a...Objective: The purpose of this study was to explore the optimal cutoffs of the three parameters of Ki67 during NAC for predicting patient prognosis and investigate whether the optimal cutoffs of the Ki67 values were associated with relapse-free survival(RFS) or breast cancer-specific survival(BCSS).Methods: A total of 92 patients with locally advanced breast cancer(LABC), who had residual disease after NAC were retrospectively investigated.The optimal cutoff values of the Ki67 parameters were assessed by the online algorithm Cutoff Finder.Kaplan-Meier analysis, the log-rank test and Cox regression analysis were carried out to analyze survival.Results: The optimal cutoff values for the postsurgical Ki67 level and the decrease in the Ki67 level during NAC were defined as 25% and 12.5%, respectively.According to the univariate survival analysis, a higher Ki67 level in residual disease was associated with poor RFS(P = 0.004) and BCSS(P = 0.014).In addition, a Ki67 expression decrease > 12.5% during NAC was related to favorable RFS(P = 0.007), but was not related to BCSS(P = 0.452).Cox regression analysis showed that the Ki67 expression decrease(> 12.5% vs.≤ 12.5%) and histological grade(grade 3 vs.grade 1-2) were the independent factors associated with RFS(P =0.020 and P = 0.023, respectively), with HR values of 0.353(95% CI: 0.147-0.850) and 3.422(95% CI: 1.188-9.858), respectively.Conclusions: The Ki67 decrease was one of the independent factors associated with RFS in LABC patients with residual disease after receiving NAC.展开更多
Objective: The purpose of the study was to investigate the relationship between the expression of estrogen receptor(ER), progestogen receptor(PR), human epidermal growth factor receptor(Her-2), Ki-67 and the effect of...Objective: The purpose of the study was to investigate the relationship between the expression of estrogen receptor(ER), progestogen receptor(PR), human epidermal growth factor receptor(Her-2), Ki-67 and the effect of neoadjuvant chemotherapy in breast cancer. Methods: The expression of ER, PR, Her-2 and Ki-67 in 45 breast cancers which received neoadjuvant chemotherapy was detected by immunohistochemistry. Results: The effective rates in ER negative and PR negative groups were higher than those in ER positive and PR positive groups(83.3% vs 59. 4%, 82.4% vs 60.6%). There was no significant difference of the effective rate between Her-2 overexpressed group and Her-2 non-overexpressed group(81.8% vs 64.1%), and the same thing happened between Ki-67 negative group and Ki-67 positive group(67.7% vs 63.2%). Conclusion: In the patients with breast cancer, ER, PR negative ones were more sensitive to neoadjuvant chemotherapy. These patients may get more benefits from chemotherapy. ER, PR could be feasible markers for predicting the effective rate of neoadjuvant chemotherapy.展开更多
A potential strategy for patients with estrogen receptor(ER)-positive breast cancer is necessary to replace neoadjuvant chemotherapy which has limited benefit.Neoadjuvant endocrine therapy(NAE)has been indicated to be...A potential strategy for patients with estrogen receptor(ER)-positive breast cancer is necessary to replace neoadjuvant chemotherapy which has limited benefit.Neoadjuvant endocrine therapy(NAE)has been indicated to be a favorable alternate approach to downstage large or locally advanced breast cancer in ER-positive,human epidermal growth factor receptor 2(HER2)-negative(ER+/HER2-)patients,especially postmenopausal women.Previous studies have demonstrated the efficacy of various endocrine agents in NAE.Aromatase inhibitors(AIs)have proven superiority over tamoxifen as a suitable choice to optimize treatment efficacy.Fulvestrant was recently reported as an effective agent,similar to AIs.Furthermore,the addition of targeted agents exerts synergistic antiproliferative effects with endocrine agents and rapidly improves response rates in both endocrine sensitive and resistant tumors.The neoadjuvant platform provides a unique opportunity to define the appropriate strategy and address the mechanisms of endocrine resistance.In addition,the predictive value of biomarkers and genomic assays in NAE is under investigation to evaluate individual effects and validate biomarker-based strategies.In this review,we discuss the most relevant evidence on the potential of NAE for ER+breast cancer.The current understanding also offers new insights into the identification of the optimal settings and valuable predictive tools of NAE to guide clinical treatment decisions and achieve beneficial therapeutic effects.展开更多
目的探讨乳腺癌摄取^(99)Tc^(m)-甲氧异腈(MIBI)与Ki-67抗原表达的关系,并验证Ki-67预测新辅助化疗(NAC)疗效的价值。方法回顾性分析2018年1月至2020年3月于宁夏医科大学总医院就诊的47例乳腺癌患者NAC前后双时相^(99)Tc^(m)-MIBI SPECT...目的探讨乳腺癌摄取^(99)Tc^(m)-甲氧异腈(MIBI)与Ki-67抗原表达的关系,并验证Ki-67预测新辅助化疗(NAC)疗效的价值。方法回顾性分析2018年1月至2020年3月于宁夏医科大学总医院就诊的47例乳腺癌患者NAC前后双时相^(99)Tc^(m)-MIBI SPECT/CT断层融合显像,分析T/N比值和肿瘤大小在治疗前后的变化及与Ki-67之间的关系。采用两样本t检验、直线相关性及χ^(2)检验分析数据。结果乳腺癌^(99)Tc^(m)-MIBI显像NAC前后20 min T/N比值、2 h T/N比值下降差异有统计意义(P<0.05),肿瘤NAC化疗前后最大径缩小差异有统计学意义(P<0.05);Ki-67高表达组与低表达组患者NAC后T/N比值下降和肿瘤缩小差异均有统计学意义(P<0.05);Ki-67的表达与20 min和2 h T/N比值有相关性(P<0.05)。结论Ki-67抗原表达和乳腺^(99)Tc^(m)-MIBI显像有助于了解肿瘤增殖,Ki-67抗原表达对NAC疗效有预测价值,可用于指导临床治疗。展开更多
Background This study was designed in an attempt to determine the influence of neoadjuvant chemotherapy on estrogen receptor （ER）, progesterone receptor （PR）, human epidermal growth factor receptor 2 （Her-2）, an...Background This study was designed in an attempt to determine the influence of neoadjuvant chemotherapy on estrogen receptor （ER）, progesterone receptor （PR）, human epidermal growth factor receptor 2 （Her-2）, and Ki-67 expressions in patients with breast cancer. Methods Pre- and post-neoadjuvant chemotherapy, paired-tumor specimens from 103 patients with breast cancer administrated with anthracycline or anthracycline combined taxane regimen were collected. Immunohistochemical staining for ER, PR, Her-2, and Ki-67 was performed by the DAKO EnVision method. Results Among the 103 cases, five patients （4.9%） had a complete response （CR）, 82 （79.6%） partial response （PR）, 15 （14.6%） stable disease （SD）, and one （0.9%） progressive disease （PD）, yielding an overall response rate （CR ＋ PR） of 84.5%. Nine patients achieved pathological CR. There was a significant decrease in the average index of Ki-67 post- neoadjuvant chemotherapy, compared with that before chemotherapy （24.1% vs. 39.7%, P 〈0.001）. After neoadjuvant chemotherapy, the changes of Ki-67 in different subtypes of breast cancer were different （P 〈0.001）, and these changes correlated with response to neoadjuvant chemotherapy （P 〈0.001）. No significant changes in immunohistochemical expression were observed for ER, PR and Her-2. Conclusions Neoadjuvant chemotherapy apparently reduced Ki-67 index in primary breast carcinomas, but profiles for ER, PR and Her-2 were not significantly different before and after neoadjuvant chemotherapy. The change of Ki- 67 correlated with molecular subtypes and response to neoadjuvant chemotherapy, suggesting that Ki-67 index was a surrogate marker to predict the treatment response of neoadjuvant chemotherapy.展开更多
目的:探讨乳腺癌组织中乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)和Ki-67的表达与新辅助化疗疗效之间的关系。方法:回顾性分析我科2012年10月至2014年8月收治的Ⅱ-Ⅲ期乳腺癌新辅助化疗患者65例,采用免疫组化方法检测BCRP...目的:探讨乳腺癌组织中乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)和Ki-67的表达与新辅助化疗疗效之间的关系。方法:回顾性分析我科2012年10月至2014年8月收治的Ⅱ-Ⅲ期乳腺癌新辅助化疗患者65例,采用免疫组化方法检测BCRP和Ki-67的表达,分析BCRP、Ki-67的表达水平与新辅助化疗疗效的关系。结果:原发性乳腺癌组织中BCRP的阳性表达率为67.7%。BCRP的表达水平与新辅助化疗后病理组织学反应有关,组织学显著反应组(病理反应4~5级)BCRP的表达水平明显低于非显著反应组(病理反应1~3级),差异有统计学意义(χ~2=12.77,P=0.001)。化疗前Ki-67高表达组临床缓解率明显高于低表达组(χ~2=17.72,P<0.00)。结论:联合检测乳腺癌组织中BCRP和Ki-67的表达水平对新辅助化疗疗效有一定的预测价值。展开更多
背景与目的：新辅助化疗（neo-adjuvant chemotherapy,NAC）在局部进展期乳腺癌（locally advanced breast cancer,LABC）中的作用已经很明确,达到病理完全缓解者可提高生存率,因而,临床上能否找到可以预测新辅助化疗效果的指标显得日...背景与目的：新辅助化疗（neo-adjuvant chemotherapy,NAC）在局部进展期乳腺癌（locally advanced breast cancer,LABC）中的作用已经很明确,达到病理完全缓解者可提高生存率,因而,临床上能否找到可以预测新辅助化疗效果的指标显得日益重要。对于雌、孕激素受体（ER,PR）和人类表皮生长因子受体（HER2）表达与新辅助化疗疗效之间的相关性一直存在争论,至今尚未统一。近年研究提示缩短化疗间期实施密集化疗将有希望进一步提高疗效,因此,本研究中采用表柔比星（EPI）加紫杉醇（PTX）双周ET联合方案新辅助化疗治疗LABC,同时比较ER/PR、HER2表达与疗效的相关性。方法：将82例未经治疗的Ⅱb~Ⅲb期LABC患者入组双周ET联合新辅助化疗,其方案为EPI50mg/m^2,第1天,静脉注射;PTX175mg/m^2,第2天,静脉滴注3h,每2周重复1次,均接受3个周期化疗后评估,观察其疗效、不良反应以及比较ER/PR和HER2表达与疗效和预后的相关性。结果：肿瘤原发灶总有效率（RR）为85.4%,临床完全缓解（cCR）19.5%,部分缓解（PR）65.9%,病理完全缓解（pCR）12.2%。36.5%发生白细胞减少症（3-4级）,3.7%出现白细胞减少性发热,心脏毒性较轻微,有4例（4.9%）发生心脏毒性（1级）,1例发生心脏毒性（2级）,末梢周围神经损害44.9%,主要为1～2级,所有患者完成了3个周期化疗后接受手术。ER、PR表达分别与pCR呈明显相关性（P=0.017,P=0.004）,ER、PR阴性表达者pCR的概率明显大于阳性表达者。ER和PR双阴性者pCR的概率较ER和（或）PR阳性表达者有显著性增高（P=0.001）。HER2过表达者pCR率为27.3%,明显高于低表达者的6.7%（P=0.020）。结合分子亚型比较,三阴性组和HER2过表达组pCR明显高于LuminalA和LuminalB。获得pCR患者中,HER2过表达和无表达者的5年无病生存率（DFS）和总生存率（OS）差异无统计学意义,相反,在非pCR患者中,HER2过表达者DFS、OS却明显低于HER2无表达者。结论：双周ET联合方案在LABC的新辅助化疗中疗效显著,耐受性良好,ER、PR和HER状态能较好预测pCR,HER2过表达者提高了获得pCR患者的生存率,而未获得pCR的患者预后更差。展开更多
基金supported by National Natural Science Foundation of China (NSFC) (81372851)
文摘This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor（ER）, progesterone receptor（PR） and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry.Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2%（79/521）, 26.9%（140/520） and 44.8%（225/502）, respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5%（39/521）, 13.3%（69/520） and 21.1%（106/502） of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7%（40/521）, 13.6%（71/520）and 23.7%（119/502） of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.
基金supported by grants from the Department of Education of Guangdong Province (Grant No.2016KQNCX051)Key International Collaborative Project of National Natural Science Fund Committee (Grant No.81320108015)+1 种基金National Natural Science Foundation of China (Grant No.31271068)Natural Science Foundation of Guangdong Province (Grant No.2015A030313429)
文摘Objective: The purpose of this study was to explore the optimal cutoffs of the three parameters of Ki67 during NAC for predicting patient prognosis and investigate whether the optimal cutoffs of the Ki67 values were associated with relapse-free survival(RFS) or breast cancer-specific survival(BCSS).Methods: A total of 92 patients with locally advanced breast cancer(LABC), who had residual disease after NAC were retrospectively investigated.The optimal cutoff values of the Ki67 parameters were assessed by the online algorithm Cutoff Finder.Kaplan-Meier analysis, the log-rank test and Cox regression analysis were carried out to analyze survival.Results: The optimal cutoff values for the postsurgical Ki67 level and the decrease in the Ki67 level during NAC were defined as 25% and 12.5%, respectively.According to the univariate survival analysis, a higher Ki67 level in residual disease was associated with poor RFS(P = 0.004) and BCSS(P = 0.014).In addition, a Ki67 expression decrease > 12.5% during NAC was related to favorable RFS(P = 0.007), but was not related to BCSS(P = 0.452).Cox regression analysis showed that the Ki67 expression decrease(> 12.5% vs.≤ 12.5%) and histological grade(grade 3 vs.grade 1-2) were the independent factors associated with RFS(P =0.020 and P = 0.023, respectively), with HR values of 0.353(95% CI: 0.147-0.850) and 3.422(95% CI: 1.188-9.858), respectively.Conclusions: The Ki67 decrease was one of the independent factors associated with RFS in LABC patients with residual disease after receiving NAC.
文摘Objective: The purpose of the study was to investigate the relationship between the expression of estrogen receptor(ER), progestogen receptor(PR), human epidermal growth factor receptor(Her-2), Ki-67 and the effect of neoadjuvant chemotherapy in breast cancer. Methods: The expression of ER, PR, Her-2 and Ki-67 in 45 breast cancers which received neoadjuvant chemotherapy was detected by immunohistochemistry. Results: The effective rates in ER negative and PR negative groups were higher than those in ER positive and PR positive groups(83.3% vs 59. 4%, 82.4% vs 60.6%). There was no significant difference of the effective rate between Her-2 overexpressed group and Her-2 non-overexpressed group(81.8% vs 64.1%), and the same thing happened between Ki-67 negative group and Ki-67 positive group(67.7% vs 63.2%). Conclusion: In the patients with breast cancer, ER, PR negative ones were more sensitive to neoadjuvant chemotherapy. These patients may get more benefits from chemotherapy. ER, PR could be feasible markers for predicting the effective rate of neoadjuvant chemotherapy.
基金Supported by the National Natural Science Foundation of China,No.81773083
文摘A potential strategy for patients with estrogen receptor(ER)-positive breast cancer is necessary to replace neoadjuvant chemotherapy which has limited benefit.Neoadjuvant endocrine therapy(NAE)has been indicated to be a favorable alternate approach to downstage large or locally advanced breast cancer in ER-positive,human epidermal growth factor receptor 2(HER2)-negative(ER+/HER2-)patients,especially postmenopausal women.Previous studies have demonstrated the efficacy of various endocrine agents in NAE.Aromatase inhibitors(AIs)have proven superiority over tamoxifen as a suitable choice to optimize treatment efficacy.Fulvestrant was recently reported as an effective agent,similar to AIs.Furthermore,the addition of targeted agents exerts synergistic antiproliferative effects with endocrine agents and rapidly improves response rates in both endocrine sensitive and resistant tumors.The neoadjuvant platform provides a unique opportunity to define the appropriate strategy and address the mechanisms of endocrine resistance.In addition,the predictive value of biomarkers and genomic assays in NAE is under investigation to evaluate individual effects and validate biomarker-based strategies.In this review,we discuss the most relevant evidence on the potential of NAE for ER+breast cancer.The current understanding also offers new insights into the identification of the optimal settings and valuable predictive tools of NAE to guide clinical treatment decisions and achieve beneficial therapeutic effects.
文摘目的探讨乳腺癌摄取^(99)Tc^(m)-甲氧异腈(MIBI)与Ki-67抗原表达的关系,并验证Ki-67预测新辅助化疗(NAC)疗效的价值。方法回顾性分析2018年1月至2020年3月于宁夏医科大学总医院就诊的47例乳腺癌患者NAC前后双时相^(99)Tc^(m)-MIBI SPECT/CT断层融合显像,分析T/N比值和肿瘤大小在治疗前后的变化及与Ki-67之间的关系。采用两样本t检验、直线相关性及χ^(2)检验分析数据。结果乳腺癌^(99)Tc^(m)-MIBI显像NAC前后20 min T/N比值、2 h T/N比值下降差异有统计意义(P<0.05),肿瘤NAC化疗前后最大径缩小差异有统计学意义(P<0.05);Ki-67高表达组与低表达组患者NAC后T/N比值下降和肿瘤缩小差异均有统计学意义(P<0.05);Ki-67的表达与20 min和2 h T/N比值有相关性(P<0.05)。结论Ki-67抗原表达和乳腺^(99)Tc^(m)-MIBI显像有助于了解肿瘤增殖,Ki-67抗原表达对NAC疗效有预测价值,可用于指导临床治疗。
文摘Background This study was designed in an attempt to determine the influence of neoadjuvant chemotherapy on estrogen receptor （ER）, progesterone receptor （PR）, human epidermal growth factor receptor 2 （Her-2）, and Ki-67 expressions in patients with breast cancer. Methods Pre- and post-neoadjuvant chemotherapy, paired-tumor specimens from 103 patients with breast cancer administrated with anthracycline or anthracycline combined taxane regimen were collected. Immunohistochemical staining for ER, PR, Her-2, and Ki-67 was performed by the DAKO EnVision method. Results Among the 103 cases, five patients （4.9%） had a complete response （CR）, 82 （79.6%） partial response （PR）, 15 （14.6%） stable disease （SD）, and one （0.9%） progressive disease （PD）, yielding an overall response rate （CR ＋ PR） of 84.5%. Nine patients achieved pathological CR. There was a significant decrease in the average index of Ki-67 post- neoadjuvant chemotherapy, compared with that before chemotherapy （24.1% vs. 39.7%, P 〈0.001）. After neoadjuvant chemotherapy, the changes of Ki-67 in different subtypes of breast cancer were different （P 〈0.001）, and these changes correlated with response to neoadjuvant chemotherapy （P 〈0.001）. No significant changes in immunohistochemical expression were observed for ER, PR and Her-2. Conclusions Neoadjuvant chemotherapy apparently reduced Ki-67 index in primary breast carcinomas, but profiles for ER, PR and Her-2 were not significantly different before and after neoadjuvant chemotherapy. The change of Ki- 67 correlated with molecular subtypes and response to neoadjuvant chemotherapy, suggesting that Ki-67 index was a surrogate marker to predict the treatment response of neoadjuvant chemotherapy.
文摘目的:探讨乳腺癌组织中乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)和Ki-67的表达与新辅助化疗疗效之间的关系。方法:回顾性分析我科2012年10月至2014年8月收治的Ⅱ-Ⅲ期乳腺癌新辅助化疗患者65例,采用免疫组化方法检测BCRP和Ki-67的表达,分析BCRP、Ki-67的表达水平与新辅助化疗疗效的关系。结果:原发性乳腺癌组织中BCRP的阳性表达率为67.7%。BCRP的表达水平与新辅助化疗后病理组织学反应有关,组织学显著反应组(病理反应4~5级)BCRP的表达水平明显低于非显著反应组(病理反应1~3级),差异有统计学意义(χ~2=12.77,P=0.001)。化疗前Ki-67高表达组临床缓解率明显高于低表达组(χ~2=17.72,P<0.00)。结论:联合检测乳腺癌组织中BCRP和Ki-67的表达水平对新辅助化疗疗效有一定的预测价值。
文摘背景与目的：新辅助化疗（neo-adjuvant chemotherapy,NAC）在局部进展期乳腺癌（locally advanced breast cancer,LABC）中的作用已经很明确,达到病理完全缓解者可提高生存率,因而,临床上能否找到可以预测新辅助化疗效果的指标显得日益重要。对于雌、孕激素受体（ER,PR）和人类表皮生长因子受体（HER2）表达与新辅助化疗疗效之间的相关性一直存在争论,至今尚未统一。近年研究提示缩短化疗间期实施密集化疗将有希望进一步提高疗效,因此,本研究中采用表柔比星（EPI）加紫杉醇（PTX）双周ET联合方案新辅助化疗治疗LABC,同时比较ER/PR、HER2表达与疗效的相关性。方法：将82例未经治疗的Ⅱb~Ⅲb期LABC患者入组双周ET联合新辅助化疗,其方案为EPI50mg/m^2,第1天,静脉注射;PTX175mg/m^2,第2天,静脉滴注3h,每2周重复1次,均接受3个周期化疗后评估,观察其疗效、不良反应以及比较ER/PR和HER2表达与疗效和预后的相关性。结果：肿瘤原发灶总有效率（RR）为85.4%,临床完全缓解（cCR）19.5%,部分缓解（PR）65.9%,病理完全缓解（pCR）12.2%。36.5%发生白细胞减少症（3-4级）,3.7%出现白细胞减少性发热,心脏毒性较轻微,有4例（4.9%）发生心脏毒性（1级）,1例发生心脏毒性（2级）,末梢周围神经损害44.9%,主要为1～2级,所有患者完成了3个周期化疗后接受手术。ER、PR表达分别与pCR呈明显相关性（P=0.017,P=0.004）,ER、PR阴性表达者pCR的概率明显大于阳性表达者。ER和PR双阴性者pCR的概率较ER和（或）PR阳性表达者有显著性增高（P=0.001）。HER2过表达者pCR率为27.3%,明显高于低表达者的6.7%（P=0.020）。结合分子亚型比较,三阴性组和HER2过表达组pCR明显高于LuminalA和LuminalB。获得pCR患者中,HER2过表达和无表达者的5年无病生存率（DFS）和总生存率（OS）差异无统计学意义,相反,在非pCR患者中,HER2过表达者DFS、OS却明显低于HER2无表达者。结论：双周ET联合方案在LABC的新辅助化疗中疗效显著,耐受性良好,ER、PR和HER状态能较好预测pCR,HER2过表达者提高了获得pCR患者的生存率,而未获得pCR的患者预后更差。
